Concepedia

Author

Jean‐Yves Douillard

Institut Gustave RoussyORCID

Also Known As

Bot, Brian M., F. M. Vallette, J DOUILLARD, J Douillard, J Y Douillard, J. -Y. Douillard, J. Douillard, J. Y. Douillard, J. Y. Y. Douillard, J.-Y Douillard

384

Publications

33.1K

Citations

69

H-Index

90

Concepts

All Affiliations

Institut Gustave RoussyInstitut de Cancérologie de l'OuestInstitut Génétique Nantes AtlantiqueInsermCentre Hospitalier René-Dubos
JD

About

Jean‐Yves Douillard is an author at Institut Gustave Roussy specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

38

95

14.3K

2

Health Sciences

26

38

6.7K

3

Public Health

2

2

57

4

Biostatistics

2

2

58

5

Allergy

1

1

10

Jean‐Yves Douillard

×

145

Publications

29.6K

Citations

58

H-Index

YearCitations

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

Eric Van Cutsem, Andrés Cervantes, René Adam,

Annals of Oncology

2016

3.3K

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone,

Journal of Clinical Oncology

2003

2.9K

Panitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer

Jean‐Yves Douillard, Kelly S. Oliner, Salvatore Siena,

New England Journal of Medicine

2013

2.2K

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy,

Journal of Clinical Oncology

2010

1.8K

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena,

The Lancet Oncology

2006

1.6K

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein,

Annals of Oncology

2012

1.5K

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim, Vera Hirsh, Tony Mok,

The Lancet

2008

1.2K

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Lawrence H. Schwartz, Sergio Ricci,

Journal of Clinical Oncology

2006

1.2K

Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma

Sylvie Négrier, Bernard Escudier, Christine Lasset,

New England Journal of Medicine

1998

965

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard,

The Lancet Oncology

2014

931

Page 1